Interestingly, while RPS6KB1 amplification had comparable survival impacts in the previously mentioned cancers, RPS6KB2 amplification was associated with lower survival rates in esophagogastric and ovarian cancers (Figure 5A). Here, RPS6KB2 is linked to cancer.